Clinical trial
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT05141721 is registered in ClinicalTrials.gov with Seattle Project Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- Lead sponsor
- Seattle Project Corporation
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- February 12, 2022
- Completion date
- March 31, 2027
- Enrollment
- 700 (estimated)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.